Evidence map›Paper›PMID 28286068›Full record

SynthesisThe Journal of urology2017

Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.

Brock E Boehm, John E Cornell, Hanzhang Wang, Neelam Mukherjee, Jacob S Oppenheimer, Robert S Svatek

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Review of BCG immunotherapy for bladder cancer.Clinical microbiology reviews · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brock E BoehmDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas.
John E CornellDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas.
Hanzhang WangDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas.
Neelam MukherjeeDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas.
Jacob S OppenheimerDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas.
Robert S SvatekDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas; Department of Biostatistics (JEC), University of Texas Health San Antonio, San Antonio, Texas. Electronic address: svatek@uthscsa.edu.

Funding

Improving immunotherapy in bladder cancer by targeting immune dysfunctionK23CA178204 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SVATEK, ROBERT SCOTT · 2014 to 2017
$674k
NCI NIH HHS K23 CA178204
6 · The paper itself

Abstract

purposeWe sought to determine the efficacy of genetically distinct bacillus Calmette-Guérin strains in preventing disease recurrence in patients with nonmuscle invasive bladder cancer. MATERIALS AND

methodsWe conducted a systematic review and network meta-analysis of trials evaluating bacillus Calmette-Guérin strains against all possible comparators (different bacillus Calmette-Guérin strains, chemotherapy and nonbacillus Calmette-Guérin biological therapies) with intravesical chemotherapy as the common comparator. MEDLINE® (http://www.ncbi.nlm.nih.gov/pubmed) served as the primary data source, with the search from inception to October 2016 for clinical trials involving patients with nonmuscle invasive bladder cancer receiving bacillus Calmette-Guérin. Primary outcome measure was bladder cancer recurrence, defined as recurrent bladder tumor of any grade or stage. Random effect network meta-analysis provided estimates for outcomes and is presented as odds ratios.

resultsAcross all possible comparators (65 trials, 12,246 patients, 9 strains) there were 2,177 recurrences in 5,642 treated patients (38.6%) and 2,316 recurrences in 5,441 comparators (42.6%). With chemotherapy as the common comparator (28 trials, 5,757 patients, 5 strains) Tokyo-172 (OR 0.39, 95% CI 0.16-0.93), Pasteur (OR 0.49, 95% CI 0.28-0.86) and TICE® (OR 0.61, 95% CI 0.40-0.93) strains were significantly better than chemotherapy at preventing recurrence. No bacillus Calmette-Guérin strain demonstrated significant superiority when compared to any other strain at preventing recurrence in the network meta-analysis.

conclusionsBacillus Calmette-Guérin strains exhibited significant differences in efficacy compared to chemotherapy. However, no definitive conclusions could be reached regarding strain superiority, and head-to-head trials are greatly needed to further understand the importance of strain selection in determining bacillus Calmette-Guérin efficacy.

Indexed as

Adjuvants, ImmunologicBCG VaccineHumansMycobacterium bovisUrinary Bladder NeoplasmsAdjuvants, ImmunologicBCG VaccineBCG vaccineimmunotherapyurinary bladder neoplasms

Identifiers

PMID28286068
PMCPMC6464123

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.